Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Characteristics of Daratumumab Reactions in Patients Who Transitioned from Intravenous Daratumumab to Subcutaneous Daratumumab

Chang Kun Kim, Lindsey Douglass, Beth Gustafson, Madeline E Begemann, Furha I. Cossor, Vinay Gupta, Shahzad Raza

Blood (2021) 138 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2021-154174

Published: 2021

Journal Articles

Photopheresis As Part of Conditioning Reduces Incidence of Severe Graft Versus Host Disease: Fourteen Year Follow-up of a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Esha Kaul, MD, Gunjan L Shah, MDMS, Aaron S. Rosenberg, MD, Raymond L. Comenzo, MD, Hedy Smith, MD PhD, Andrew M. Evens, DO, MSc, Furha I. Cossor, MD, Grace S. Kao, MD, Kenneth B. Miller, MD, Andreas K. Klein, MD, Kellie A. Sprague, MD

Blood (2014) 124 (21): 5924.

https://doi.org/10.1182/blood.V124.21.5924.5924

Published: 2014

Journal Articles

Small Molecule Activation Of Pyruvate Kinase Normalizes Metabolic Activity In Red Cells From Patients With Pyruvate Kinase Deficiency-Associated Hemolytic Anemia

Charles Kung, Ph.D., Jeff Hixon, Penelope Kosinski, Gavin Histen, Collin Hill, Yaguang Si, Andrew Kernytsky, Yue Chen, Ph.D., Byron DeLaBarre, Michelle Clasquin, Helen Ho, Furha I. Cossor, MD MS, Ellis J. Neufeld, MD, PhD, Frank Salituro, Janeta Popovici-Muller, Samuel Agresta, MD, Lee Silverman, Lenny Dang

Blood (2013) 122 (21): 2180.

https://doi.org/10.1182/blood.V122.21.2180.2180

Published: 2013

Journal Articles

Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity.

Gunjan L Shah, MD MS, Esha Kaul, MD, Shelly Fallo, RPh, Furha I. Cossor, MD MS, Hedy Smith, MD PhD, Andreas K. Klein, MD, Kenneth B. Miller, MD, Raymond L. Comenzo, MD

Blood (2012) 120 (21): 2968.

https://doi.org/10.1182/blood.V120.21.2968.2968

Published: 2012

Journal Articles

Diagnosis of extracavitary primary effusion lymphoma by urine cytology

Mili Arora, Furha I. Cossor

Blood (2012) 119 (12): 2707.

https://doi.org/10.1182/blood-2011-04-319103

Published: 2012

Journal Articles

Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients ≥ 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,

Furha I. Cossor, MD, Sandy Wong, MD, Kenneth B Miller, MD, Deborah Black, RN, Raymond L. Comenzo, MD, Andreas K. Klein, MD, Alanna Klekar, RN, Valerie Relias, PharmD, Hedy Smith, MD, PhD, Kellie Sprague, MD, Karen M Switkowski, MS, MPH, Richard A. Van Etten, MD PhD, Hans-Georg Klingemann, MD, PhD

Blood (2011) 118 (21): 4153.

https://doi.org/10.1182/blood.V118.21.4153.4153

Published: 2011

Journal Articles

Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic AL Amyloidosis

Furha I. Cossor, MD, Adam Boruchov, MD, Michael Danso, MD, Michael Edward Lee, Ayan Patel, MD, Eric Winer, MD, Rodney Falk, MD, Raymond L. Comenzo, MD

Blood (2011) 118 (21): 5139.

https://doi.org/10.1182/blood.V118.21.5139.5139

Published: 2011

NARROW

Characteristics of Daratumumab Reactions in Patients Who Transitioned from Intravenous Daratumumab to Subcutaneous Daratumumab

Photopheresis As Part of Conditioning Reduces Incidence of Severe Graft Versus Host Disease: Fourteen Year Follow-up of a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Small Molecule Activation Of Pyruvate Kinase Normalizes Metabolic Activity In Red Cells From Patients With Pyruvate Kinase Deficiency-Associated Hemolytic Anemia

Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity.

Diagnosis of extracavitary primary effusion lymphoma by urine cytology

Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients ≥ 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,

Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Characteristics of Daratumumab Reactions in Patients Who Transitioned from Intravenous Daratumumab to Subcutaneous Daratumumab

Photopheresis As Part of Conditioning Reduces Incidence of Severe Graft Versus Host Disease: Fourteen Year Follow-up of a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Small Molecule Activation Of Pyruvate Kinase Normalizes Metabolic Activity In Red Cells From Patients With Pyruvate Kinase Deficiency-Associated Hemolytic Anemia

Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity.

Diagnosis of extracavitary primary effusion lymphoma by urine cytology

Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients ≥ 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,

Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only